1
|
Cristian M, Așchie M, Mitroi AF, Deacu M, Boșoteanu M, Bălțătescu GI, Stoica AG, Nicolau AA, Enciu M, Crețu AM, Caloian AD, Orășanu CI, Poinăreanu I. The impact of MYD88 and PIM1 in mature large B-cell non-Hodgkin lymphomas: Defining element of their evolution and prognosis. Medicine (Baltimore) 2024; 103:e36269. [PMID: 38335426 PMCID: PMC10860999 DOI: 10.1097/md.0000000000036269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 10/31/2023] [Accepted: 11/01/2023] [Indexed: 02/12/2024] Open
Abstract
Sequence studies of the entire exome and transcriptome of lymphoma tissues have identified MYD88 and PIM1 as involved in the development and oncogenic signaling. We aimed to determine the frequency of MYD88 and PIM1 mutations, as well as their expressions in conjunction with the clinicopathological parameters identified in mature large B-cell non-Hodgkin lymphomas. The ten-year retrospective study included 50 cases of mature large B-cell lymphoma, diagnosed at the Pathology Department of the Emergency County Hospital of Constanţa and Săcele County Hospital of Brasov. They were statistically analyzed by demographic, clinicopathological, and morphogenetic characteristics. We used a real-time polymerase chain reaction technique to identify PIM1 and MYD88 mutations as well as an immunohistochemical technique to evaluate the expressions of the 2 genes. Patients with lymphoma in the small bowel, spleen, brain, and testis had a low-performance status Eastern Cooperative Oncology Group (P = .001). The Eastern Cooperative Oncology Group performance status represented an independent risk factor predicting mortality (HR = 9.372, P < .001). An increased lactate dehydrogenase value was associated with a low survival (P = .002). The international prognostic index score represents a negative risk factor in terms of patient survival (HR = 4.654, P < .001). In cases of diffuse large B-cell lymphoma (DLBCL), immunopositivity of MYD88 is associated with non-germinal center B-cell origin (P < .001). The multivariate analysis observed the association between high lactate dehydrogenase value and the immunohistochemical expression of PIM1 or with the mutant status of the PIM1 gene representing negative prognostic factors (HR = 2.066, P = .042, respectively HR = 3.100, P = .004). In conclusion, our preliminary data suggest that the oncogenic mutations of PIM1 and MYD88 in our DLBCL cohort may improve the diagnosis and prognosis of DLBCL patients in an advanced stage.
Collapse
Affiliation(s)
- Miruna Cristian
- Faculty of Medicine, “Ovidius” University of Constanta, Constanța, Romania
- Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology – CEDMOG, “Ovidius” University of Constanta, Constanța, Romania
- Department of Clinical Pathology, “Sf. Apostol Andrei” Emergency County Hospital, Constanta, Romania
| | - Mariana Așchie
- Faculty of Medicine, “Ovidius” University of Constanta, Constanța, Romania
- Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology – CEDMOG, “Ovidius” University of Constanta, Constanța, Romania
- Department of Clinical Pathology, “Sf. Apostol Andrei” Emergency County Hospital, Constanta, Romania
- Academy of Medical Sciences, Bucharest, Romania
- Academy of Romanian Scientists, Bucharest, Romania
| | - Anca-Florentina Mitroi
- Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology – CEDMOG, “Ovidius” University of Constanta, Constanța, Romania
- Department of Clinical Pathology, “Sf. Apostol Andrei” Emergency County Hospital, Constanta, Romania
| | - Mariana Deacu
- Faculty of Medicine, “Ovidius” University of Constanta, Constanța, Romania
- Department of Clinical Pathology, “Sf. Apostol Andrei” Emergency County Hospital, Constanta, Romania
| | - Mădălina Boșoteanu
- Faculty of Medicine, “Ovidius” University of Constanta, Constanța, Romania
- Department of Clinical Pathology, “Sf. Apostol Andrei” Emergency County Hospital, Constanta, Romania
| | - Gabriela-Izabela Bălțătescu
- Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology – CEDMOG, “Ovidius” University of Constanta, Constanța, Romania
- Department of Clinical Pathology, “Sf. Apostol Andrei” Emergency County Hospital, Constanta, Romania
| | - Andreea-Georgiana Stoica
- Faculty of Medicine, “Ovidius” University of Constanta, Constanța, Romania
- Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology – CEDMOG, “Ovidius” University of Constanta, Constanța, Romania
- Department of Hematology, “Sf. Apostol Andrei” Emergency County Hospital, Constanta, Romania
| | - Anca-Antonela Nicolau
- Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology – CEDMOG, “Ovidius” University of Constanta, Constanța, Romania
- Department of Clinical Pathology, “Sf. Apostol Andrei” Emergency County Hospital, Constanta, Romania
| | - Manuela Enciu
- Faculty of Medicine, “Ovidius” University of Constanta, Constanța, Romania
- Department of Clinical Pathology, “Sf. Apostol Andrei” Emergency County Hospital, Constanta, Romania
| | - Ana-Maria Crețu
- Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology – CEDMOG, “Ovidius” University of Constanta, Constanța, Romania
- Department of Clinical Pathology, “Sf. Apostol Andrei” Emergency County Hospital, Constanta, Romania
| | - Andreea-Daniela Caloian
- Faculty of Medicine, “Ovidius” University of Constanta, Constanța, Romania
- Department of Hemato-Oncology, “Ovidius” Clinical Hospital, Constanta, Romania
| | - Cristian-Ionuț Orășanu
- Faculty of Medicine, “Ovidius” University of Constanta, Constanța, Romania
- Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology – CEDMOG, “Ovidius” University of Constanta, Constanța, Romania
- Department of Clinical Pathology, “Sf. Apostol Andrei” Emergency County Hospital, Constanta, Romania
| | - Ionuț Poinăreanu
- Faculty of Medicine, “Ovidius” University of Constanta, Constanța, Romania
- Department of Pathology, Săcele Municipal Hospital, Brasov, Romania
| |
Collapse
|
2
|
Caner V, Sen Turk N, Baris IC, Cetin GO, Tepeli E, Hacioglu S, Sari I, Zencir S, Dogu MH, Bagci G, Keskin A. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas. Genet Test Mol Biomarkers 2015; 19:372-8. [PMID: 25978699 DOI: 10.1089/gtmb.2015.0041] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Myeloid differentiation primary response 88 (MYD88) is a common adaptor protein that is responsible for signaling from several receptors; mutations in this gene may play a role in the pathogenesis of lymphoma. AIM We aimed to determine the MYD88 L265P mutation frequency, the level of MYD88 expression, and their associations with clinicopathological parameters in mature B-cell non-Hodgkin lymphomas (NHLs). METHODS A total of 68 patients were included in the study. The presence of the MYD88 L265P mutation was analyzed by real-time polymerase chain reaction and direct sequencing. MYD88 protein expression was evaluated by immunohistochemistry (IHC) using two different scoring systems. RESULTS MYD88 L265P mutation was present in eight (18.6%) diffuse large B-cell lymphoma (DLBCL) patients. We also observed a significant association between the loss of MYD88 expression and advanced stage in both mature B-cell NHL and DLBCL according to the first IHC scoring systems (p=0.015 and p=0.024, respectively). An association was also seen between MYD88 overexpression and low clinical risk in both mature B-cell NHL and DLBCL according to the second IHC scoring system (p=0.027 and p=0.024, respectively). CONCLUSIONS The L265P mutation may be helpful for understanding the pathogenesis of immune-privileged site-associated DLBCLs. The presence of the mutation, together with its protein overexpression, could also be used as a prognostic marker in advanced stage DLBCLs.
Collapse
Affiliation(s)
- Vildan Caner
- 1 Tibbi Genetik AD, Pamukkale Universitesi Hastanesi , Denizli, Turkey
| | - Nilay Sen Turk
- 2 Tibbi Patoloji AD, Pamukkale Universitesi Hastanesi , Denizli, Turkey
| | | | - Gokhan Ozan Cetin
- 1 Tibbi Genetik AD, Pamukkale Universitesi Hastanesi , Denizli, Turkey
| | - Emre Tepeli
- 1 Tibbi Genetik AD, Pamukkale Universitesi Hastanesi , Denizli, Turkey
| | - Sibel Hacioglu
- 4 Hematoloji BD, Pamukkale Universitesi Hastanesi , Denizli, Turkey
| | - Ismail Sari
- 4 Hematoloji BD, Pamukkale Universitesi Hastanesi , Denizli, Turkey
| | - Sevil Zencir
- 3 Tibbi Biyoloji AD, Pamukkale Universitesi , Denizli, Turkey
| | | | - Gulseren Bagci
- 1 Tibbi Genetik AD, Pamukkale Universitesi Hastanesi , Denizli, Turkey
| | - Ali Keskin
- 4 Hematoloji BD, Pamukkale Universitesi Hastanesi , Denizli, Turkey
| |
Collapse
|